Business Wire

FABASOFT

29.3.2021 15:35:10 CEST | Business Wire | Press release

Share
Fabasoft Listed in the Independent “Now Tech: Content Platforms, Q1 2021” Report

Fabasoft, a leading European provider of cloud solutions, was invited by Forrester to take part in an independent overview of “Content Platforms” (“The latest stage of evolution in the market traditionally known as Enterprise Content Management Systems”).

Research and advisory firm Forrester Research Inc. overviewed 38 top cloud content platforms based on platform capabilities, vertical focus, and size.

One of the key takeaways according to the authors of the “Now Tech: Content Platforms, Q1 2021” analysis* indicates that “…small and midsize vendors may offer a better range of content services and expertise in specific vertical markets.” Yet the study’s authors also offer the following words of caution: “Be wary of ‘cloudwashing’ when older technologies are hosted but branded as cloud.”

The functionality of Fabasoft Business Process Cloud as a multi-client cloud content platform covers categories addressed in the study such as “Collaborative Content Services” and “Transactional Content Services and Multitenant Cloud Content Platforms.”

Download now: Now Tech: Content Platforms, Q1 2021

“We believe being listed in the report as a native cloud provider with three of the four primary functionality segments attests to the capabilities and performance of the Fabasoft Business Process Cloud,” remarks a delighted Andreas Dangl, Business Unit Executive Cloud and digitalization expert at Fabasoft.

“With its process-driven cloud platform, Fabasoft specializes in document-centric business workflows for manufacturing, financial services, as well as architecture, engineering, and construction. Among our strengths is efficient ‘low-code’ or ‘no-code’ customizing – in other words, tailoring our products to customer requirements without the need for elaborate programming. The broad range of standard interfaces also makes it easier to connect to existing IT systems,” explains Dangl.

Forrester Now Tech is an independent and objective overview of providers focusing on a specific IT solution area.

Download now: Now Tech: Content Platforms, Q1 2021

*Forrester Now Tech: Content Platforms, Q1 2021, Cheryl McKinnon with Daniel Hong, Hailey Colin, and Sam Bartlett.

Using the Fabasoft Business Process Cloud , companies can shape their business processes and work with digital content across organizations, IT infrastructures, and countries. Fabasoft Business Process Cloud’s out-of-the-box solutions and scalable applications empower organizations to bring the focus back to their customers as they move their digital transformation forward. Companies in the industrial sector appreciate the platform’s advantages, particularly when it comes to handling major projects and implementing processes in documentation and product management. Functionalities such as workflow automation and modeling, well-defined authorization and role models, transparent versioning, automatic synchronization, and mobile use facilitate collaboration and ensure seamless transparency.

About Fabasoft

Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management. For more than three decades, numerous prominent private enterprises and public sector organizations have placed their trust in Fabasoft’s long-standing quality and experience.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye